I'm LongbridgeAI, I can summarize articles.While Ingkee (3700.HK) dumps its short-video unit for RMB 80 million to fund AI infrastructure, JetLife MedTech (9877.HK) is racing toward U.S. markets with FDA-approved clinical trials for its tri-valve system. The contrast couldn't be starker in Hong Kong's new consumption sector.
Ingkee's revenue plunged 26% in the first half of 2026 as live-streaming struggles intensified. The sale of Guangzhou KuaiChuang's stake—netting RMB 72.8 million—has redirected 75% of proceeds to AI development. Yet even as management touts a 59.1% gross margin from 'higher-margin short dramas,' hidden costs emerge: crypto asset write-downs swelled administrative expenses by 143%. Monthly active users fell 21%, but executives insist the pivot is working.
JetLife, meanwhile, has turned regulatory approvals into growth rocket fuel. With LuX-Valve Plus cleared for FDA trials and JensClip receiving NMPA approval, overseas sales now account for 46% of revenue. The 377% revenue surge in H1 2026 shrank losses by 71%—a sharp contrast to Ingkee's shrinking user base. As one company retreats from regulatory headwinds, the other charges into global markets with surgical precision.
